Handelen AstraZeneca PLC - GBP - AZNl CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.30 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.023178% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.00126% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | GBP | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
AstraZeneca PLC ESG Risk Ratings
High Medium Low Negligible
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Belangrijkste statistieken
| Prev. Close* | 113.22 |
| Open* | 114.62 |
| 1-Jaarlijkse Verandering* | 9.78% |
| Dagelijks bereik* | 114.62 - 117.46 |
| 52 wekelijks bereik | 93.99-128.29 |
| Weekgemiddelde volume (10 dagen) | 1.33M |
| Gemiddeld volume (3 maanden) | 32.40M |
| Marktkapitalisatie | 180.71B |
| P/E Ratio | 48.08 |
| Uitstaande Aandelen | 1.55B |
| Omzet | 35.25B |
| EPS | 2.43 |
| Dividend (opbrengst %) | 2.05146 |
| Beta | 0.26 |
| Volgende inkomsten datum | Jul 28, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| May 31, 2023 | 116.78 | 2.22 | 1.94% | 114.56 | 117.54 | 114.30 |
| May 30, 2023 | 113.22 | -4.28 | -3.64% | 117.50 | 118.28 | 113.22 |
| May 26, 2023 | 116.62 | -0.10 | -0.09% | 116.72 | 118.18 | 116.10 |
| May 25, 2023 | 116.08 | -0.70 | -0.60% | 116.78 | 118.08 | 115.64 |
| May 24, 2023 | 116.34 | -2.04 | -1.72% | 118.38 | 119.14 | 116.34 |
| May 23, 2023 | 119.79 | 0.42 | 0.35% | 119.37 | 121.71 | 118.86 |
| May 22, 2023 | 119.77 | 0.22 | 0.18% | 119.55 | 120.95 | 119.55 |
| May 19, 2023 | 120.21 | 0.62 | 0.52% | 119.59 | 120.61 | 119.22 |
| May 18, 2023 | 119.60 | 0.11 | 0.09% | 119.49 | 120.83 | 119.49 |
| May 17, 2023 | 118.62 | -2.43 | -2.01% | 121.05 | 121.69 | 118.50 |
| May 16, 2023 | 120.31 | 1.10 | 0.92% | 119.21 | 120.89 | 119.21 |
| May 15, 2023 | 119.80 | -0.21 | -0.17% | 120.01 | 120.49 | 119.58 |
| May 12, 2023 | 119.72 | 0.56 | 0.47% | 119.16 | 120.75 | 119.06 |
| May 11, 2023 | 119.12 | 0.44 | 0.37% | 118.68 | 119.87 | 118.52 |
| May 10, 2023 | 117.98 | 0.00 | 0.00% | 117.98 | 118.64 | 116.92 |
| May 9, 2023 | 118.74 | 1.22 | 1.04% | 117.52 | 119.28 | 117.52 |
| May 5, 2023 | 118.92 | 0.90 | 0.76% | 118.02 | 118.94 | 116.98 |
| May 4, 2023 | 118.34 | 0.02 | 0.02% | 118.32 | 118.66 | 117.42 |
| May 3, 2023 | 118.68 | 0.24 | 0.20% | 118.44 | 118.92 | 117.66 |
| May 2, 2023 | 117.74 | -0.02 | -0.02% | 117.76 | 118.42 | 116.74 |
AstraZeneca PLC - GBP Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Monday, June 5, 2023 | ||
| Tijd (UTC) (UTC) 23:00 | Land GB
| Evenement AstraZeneca PLC at ASCO Investor Meeting (Virtual) AstraZeneca PLC at ASCO Investor Meeting (Virtual)Forecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 44351 | 37417 | 26617 | 24384 | 22090 |
| Inkomsten | 44351 | 37417 | 26617 | 24384 | 22090 |
| Kosten van opbrengsten, totaal | 8649 | 9542 | 5270 | 4824 | 4246 |
| Brutowinst | 35702 | 27875 | 21347 | 19560 | 17844 |
| Totale bedrijfskosten | 40594 | 36361 | 21455 | 21460 | 18703 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 13512 | 11519 | 9338 | 8964 | 8479 |
| Onderzoek & Ontwikkeling | 9612 | 8519 | 6094 | 5320 | 5266 |
| Depreciation / Amortization | 4094 | 3044 | 1897 | 1812 | 1945 |
| Ongebruikelijke uitgaven (inkomsten) | 4820 | 3846 | -763 | 863 | -953 |
| Other Operating Expenses, Total | -93 | -109 | -381 | -323 | -280 |
| Bedrijfsresultaat | 3757 | 1056 | 5162 | 2924 | 3387 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -815 | -819 | -716 | -766 | -775 |
| Overige, Netto | -441 | -502 | -530 | -610 | -619 |
| Netto inkomen voor belastingen | 2501 | -265 | 3916 | 1548 | 1993 |
| Netto inkomen na belastingen | 3293 | 115 | 3144 | 1227 | 2050 |
| Minderheidsbelang | -5 | -3 | 52 | 108 | 105 |
| Netto inkomen voor extra. Posten | 3288 | 112 | 3196 | 1335 | 2155 |
| Netto inkomen | 3288 | 112 | 3196 | 1335 | 2155 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 3288 | 112 | 3196 | 1335 | 2155 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 3288 | 112 | 3196 | 1335 | 2155 |
| Verwateringsaanpassing | 0 | 0 | |||
| Verwaterd Netto Inkomen | 3288 | 112 | 3196 | 1335 | 2155 |
| Verwaterd Gewogen Gemiddelde Aandelen | 1560 | 1427 | 1313 | 1301 | 1267 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 2.10769 | 0.07849 | 2.43412 | 1.02613 | 1.70087 |
| Dividends per Share - Common Stock Primary Issue | 2.89361 | 2.84245 | 2.83031 | 2.89446 | 2.74532 |
| Verwaterde Genormaliseerde Winst per Aandeel | 3.8859 | 2.22705 | 1.88804 | 1.48501 | 0.85399 |
| Rentekosten (inkomsten) - Operationeel nettobedrijfsresultaat | 0 | 0 | |||
| Totale buitengewone posten |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 10879 | 11207 | 10982 | 10771 | 11390 |
| Inkomsten | 10879 | 11207 | 10982 | 10771 | 11390 |
| Kosten van opbrengsten, totaal | 2053 | 2417 | 2118 | 1904 | 2279 |
| Brutowinst | 8826 | 8790 | 8864 | 8867 | 9111 |
| Totale bedrijfskosten | 8330 | 10113 | 9737 | 10232 | 10512 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 3196 | 3469 | 3353 | 3633 | 3057 |
| Onderzoek & Ontwikkeling | 2299 | 2638 | 2357 | 2431 | 2186 |
| Depreciation / Amortization | 954 | 1034 | 979 | 983 | 1098 |
| Ongebruikelijke uitgaven (inkomsten) | 230 | 331 | 1002 | 1298 | 1953 |
| Other Operating Expenses, Total | -402 | 224 | -72 | -17 | -61 |
| Bedrijfsresultaat | 2549 | 1094 | 1245 | 539 | 878 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -287 | -316 | -323 | -292 | -325 |
| Netto inkomen voor belastingen | 2262 | 778 | 922 | 247 | 553 |
| Netto inkomen na belastingen | 1804 | 902 | 1642 | 360 | 388 |
| Minderheidsbelang | -1 | -1 | -2 | 0 | -2 |
| Netto inkomen voor extra. Posten | 1803 | 901 | 1640 | 360 | 386 |
| Netto inkomen | 1803 | 901 | 1640 | 360 | 386 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 1803 | 901 | 1640 | 360 | 386 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 1803 | 901 | 1640 | 360 | 386 |
| Verwateringsaanpassing | |||||
| Verwaterd Netto Inkomen | 1803 | 901 | 1640 | 360 | 386 |
| Verwaterd Gewogen Gemiddelde Aandelen | 1560 | 1560 | 1559 | 1560 | 1561 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 1.15577 | 0.57756 | 1.05196 | 0.23077 | 0.24728 |
| Dividends per Share - Common Stock Primary Issue | 0 | 1.9694 | 0 | 0.93017 | 0 |
| Verwaterde Genormaliseerde Winst per Aandeel | 1.27335 | 0.70833 | 0.99743 | 0.80833 | 1.24792 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 22593 | 26244 | 19544 | 15563 | 15591 |
| Geldmiddelen en kortetermijnbeleggingen | 6405 | 6398 | 7992 | 6218 | 5680 |
| Cash | 1411 | 1461 | 1182 | 755 | 893 |
| Geldmiddelen & Equivalenten | 4755 | 4868 | 6650 | 4614 | 3938 |
| Korte Termijn Investeringen | 239 | 69 | 160 | 849 | 849 |
| Totale Vorderingen, Netto | 9923 | 8795 | 5651 | 5181 | 4345 |
| Accounts Receivable - Trade, Net | 7508 | 6324 | 3956 | 3813 | 2995 |
| Total Inventory | 4699 | 8983 | 4024 | 3193 | 2890 |
| Prepaid Expenses | 1329 | 1512 | 1735 | 865 | 1436 |
| Other Current Assets, Total | 237 | 556 | 142 | 106 | 1240 |
| Total Assets | 96483 | 105363 | 66729 | 61377 | 60651 |
| Property/Plant/Equipment, Total - Net | 9449 | 10171 | 8917 | 8335 | 7421 |
| Property/Plant/Equipment, Total - Gross | 17192 | 18495 | 17110 | 15852 | 14639 |
| Accumulated Depreciation, Total | -7743 | -8324 | -8193 | -7517 | -7218 |
| Goodwill, Net | 19820 | 19997 | 11845 | 11668 | 11707 |
| Intangibles, Net | 39307 | 42387 | 20947 | 20833 | 21959 |
| Long Term Investments | 1142 | 1237 | 1147 | 1459 | 922 |
| Note Receivable - Long Term | 592 | 504 | 325 | 348 | 515 |
| Other Long Term Assets, Total | 3580 | 4823 | 4004 | 3171 | 2536 |
| Total Current Liabilities | 26293 | 22594 | 20307 | 18117 | 16292 |
| Accounts Payable | 2550 | 2824 | 2350 | 1774 | 1720 |
| Accrued Expenses | 8303 | 8079 | 4994 | 5085 | 5148 |
| Notes Payable/Short Term Debt | 261 | 294 | 370 | 154 | 160 |
| Current Port. of LT Debt/Capital Leases | 5281 | 1599 | 2016 | 1856 | 1594 |
| Other Current Liabilities, Total | 9898 | 9798 | 10577 | 9248 | 7670 |
| Total Liabilities | 59446 | 66095 | 51107 | 48250 | 48183 |
| Total Long Term Debt | 23690 | 28888 | 17994 | 16217 | 17359 |
| Long Term Debt | 22965 | 28134 | 17505 | 15730 | 17359 |
| Capital Lease Obligations | 725 | 754 | 489 | 487 | 0 |
| Deferred Income Tax | 2944 | 6206 | 2918 | 2490 | 3286 |
| Minority Interest | 21 | 19 | 16 | 1469 | 1576 |
| Other Liabilities, Total | 6498 | 8388 | 9872 | 9957 | 9670 |
| Total Equity | 37037 | 39268 | 15622 | 13127 | 12468 |
| Common Stock | 387 | 387 | 328 | 328 | 317 |
| Additional Paid-In Capital | 35155 | 35126 | 7971 | 7941 | 4427 |
| Retained Earnings (Accumulated Deficit) | 1495 | 3755 | 7323 | 4858 | 7724 |
| Total Liabilities & Shareholders’ Equity | 96483 | 105363 | 66729 | 61377 | 60651 |
| Total Common Shares Outstanding | 1549.8 | 1549.4 | 1312.67 | 1312.14 | 1267.04 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 22266 | 22593 | 20224 | 20917 | 22647 |
| Geldmiddelen en kortetermijnbeleggingen | 6462 | 6405 | 4898 | 4887 | 5823 |
| Geldmiddelen & Equivalenten | 6232 | 6166 | 4458 | 4817 | 5762 |
| Korte Termijn Investeringen | 230 | 239 | 440 | 70 | 61 |
| Totale Vorderingen, Netto | 10797 | 11252 | 10061 | 9612 | 9050 |
| Accounts Receivable - Trade, Net | 10289 | 10521 | 9336 | 8908 | 8683 |
| Total Inventory | 4967 | 4699 | 5078 | 6220 | 7624 |
| Other Current Assets, Total | 40 | 237 | 187 | 198 | 150 |
| Total Assets | 96687 | 96483 | 94185 | 96579 | 100273 |
| Property/Plant/Equipment, Total - Net | 9599 | 9449 | 9227 | 9627 | 10015 |
| Goodwill, Net | 20001 | 19820 | 19707 | 19821 | 19963 |
| Intangibles, Net | 39291 | 39307 | 39585 | 39900 | 41265 |
| Long Term Investments | 1234 | 1142 | 1102 | 1180 | 1237 |
| Note Receivable - Long Term | 682 | 835 | 792 | 881 | 864 |
| Other Long Term Assets, Total | 3614 | 3337 | 3548 | 4253 | 4282 |
| Total Current Liabilities | 24860 | 26293 | 24850 | 21815 | 22740 |
| Payable/Accrued | 19210 | 19040 | 17694 | 17821 | 17864 |
| Notes Payable/Short Term Debt | 568 | 261 | 584 | 636 | 724 |
| Current Port. of LT Debt/Capital Leases | 3289 | 5281 | 5034 | 1746 | 1570 |
| Other Current Liabilities, Total | 1793 | 1711 | 1538 | 1612 | 2582 |
| Total Liabilities | 60898 | 59446 | 59051 | 60647 | 63933 |
| Total Long Term Debt | 27646 | 23690 | 23681 | 27146 | 28805 |
| Long Term Debt | 26916 | 22965 | 23013 | 26461 | 28081 |
| Capital Lease Obligations | 730 | 725 | 668 | 685 | 724 |
| Deferred Income Tax | 2795 | 2944 | 3479 | 5275 | 5626 |
| Minority Interest | 22 | 21 | 20 | 19 | 19 |
| Other Liabilities, Total | 5575 | 6498 | 7021 | 6392 | 6743 |
| Total Equity | 35789 | 37037 | 35134 | 35932 | 36340 |
| Common Stock | 387 | 387 | 387 | 387 | 387 |
| Additional Paid-In Capital | 35159 | 35155 | 35137 | 35134 | 35131 |
| Retained Earnings (Accumulated Deficit) | 243 | 1495 | -390 | 411 | 822 |
| Total Liabilities & Shareholders’ Equity | 96687 | 96483 | 94185 | 96579 | 100273 |
| Total Common Shares Outstanding | 1549.85 | 1549.8 | 1549.51 | 1549.48 | 1549.45 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | 2501 | -265 | 3916 | 1548 | 1993 |
| Geldmiddelen uit Operationele Activiteiten | 9808 | 5963 | 4799 | 2969 | 2618 |
| Geldmiddelen uit Operationele Activiteiten | 5480 | 6530 | 3149 | 3762 | 3753 |
| Niet-Geldelijke Posten | 542 | 141 | -332 | -103 | -1276 |
| Cash Taxes Paid | 1623 | 1743 | 1562 | 1118 | 537 |
| Contant Betaalde Rente | 849 | 721 | 733 | 774 | 676 |
| Veranderingen in het Operationeel Kapitaal | 1285 | -443 | -1934 | -2238 | -1852 |
| Geldmiddelen uit Investeringsactiviteiten | -2960 | -11058 | -285 | -657 | 963 |
| Kapitaaluitgaven | -2571 | -2200 | -2606 | -2460 | -1371 |
| Overige Cash Flow investeringsposten, Totaal | -389 | -8858 | 2321 | 1803 | 2334 |
| Geldmiddelen uit Financieringsactiviteiten | -6823 | 3649 | -2203 | -1765 | -2044 |
| Financiering van Cash Flow Posten | -1047 | -178 | -101 | 4 | -67 |
| Total Cash Dividends Paid | -4364 | -3856 | -3572 | -3592 | -3484 |
| Uitgifte (Aflossing) van aandelen, netto | 29 | 29 | 30 | 3525 | 34 |
| Uitgifte (Aflossing) van Schulden, Netto | -1441 | 7654 | 1440 | -1702 | 1473 |
| Wisselkoerseffecten | -80 | -62 | 12 | 5 | -38 |
| Nettowijziging in Geldmiddelen | -55 | -1508 | 2323 | 552 | 1499 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 2262 | 2501 | 1723 | 800 | 553 |
| Cash From Operating Activities | 3133 | 9808 | 7410 | 4480 | 3232 |
| Cash From Operating Activities | 1502 | 5480 | 4000 | 2666 | 1309 |
| Non-Cash Items | -391 | 542 | 172 | 15 | -12 |
| Cash Taxes Paid | 225 | 1623 | 1335 | 1006 | 228 |
| Cash Interest Paid | 257 | 849 | 608 | 386 | 194 |
| Changes in Working Capital | -240 | 1285 | 1515 | 999 | 1382 |
| Cash From Investing Activities | -1246 | -2960 | -2711 | -968 | -168 |
| Capital Expenditures | -1470 | -2571 | -2017 | -906 | -363 |
| Other Investing Cash Flow Items, Total | 224 | -389 | -694 | -62 | 195 |
| Cash From Financing Activities | -2031 | -6823 | -6465 | -5035 | -3740 |
| Financing Cash Flow Items | -840 | -1047 | -1047 | -997 | -997 |
| Total Cash Dividends Paid | -3047 | -4364 | -4364 | -2971 | -2971 |
| Issuance (Retirement) of Stock, Net | 4 | 29 | 11 | 8 | 5 |
| Issuance (Retirement) of Debt, Net | 1852 | -1441 | -1065 | -1075 | 223 |
| Foreign Exchange Effects | -11 | -80 | -86 | -35 | -9 |
| Net Change in Cash | -155 | -55 | -1852 | -1558 | -685 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5098 | 100893184 | 1200 | 2023-01-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.1999 | 65092368 | 768 | 2023-01-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 4.1199 | 63852512 | 752 | 2023-01-31 | LOW |
| Investor AB | Private Equity | 3.3299 | 51608948 | 608 | 2023-01-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8464 | 44114976 | -1215991 | 2022-12-14 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.227 | 34514808 | 15209 | 2023-05-01 | LOW |
| Capital World Investors | Investment Advisor | 1.7648 | 27351981 | 2675871 | 2022-12-14 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.2141 | 18816198 | 280706 | 2023-05-01 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.1273 | 17471628 | -78807 | 2023-05-01 | LOW |
| GQG Partners, LLC | Investment Advisor | 1.0697 | 16579162 | 1036509 | 2022-12-14 | MED |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.9835 | 15243057 | -36818 | 2023-05-01 | LOW |
| State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.6302 | 9767199 | -6522 | 2023-05-01 | LOW |
| Nuveen LLC | Pension Fund | 0.6158 | 9543355 | 495683 | 2022-12-14 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5411 | 8386244 | -95567 | 2022-12-14 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.4985 | 7725827 | -10523 | 2023-05-01 | LOW |
| Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.4931 | 7642032 | 181760 | 2023-04-30 | LOW |
| Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.4919 | 7623953 | -442236 | 2023-05-01 | LOW |
| M & G Investment Management Ltd. | Investment Advisor | 0.4722 | 7318503 | -220395 | 2023-05-01 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.4707 | 7294740 | 0 | 2023-05-01 | LOW |
| BlackRock Investment Management, LLC | Investment Advisor/Hedge Fund | 0.4379 | 6787247 | -31445 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group530K+
Handelaren
87K+
Actieve klanten per maand
$46M+
Maandelijks beleggingsvolume
$31M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
AstraZeneca - GBP Company profile
Over AstraZeneca PLC - GBP
AstraZeneca PLC (AstraZeneca) is een patiëntgericht biofarmaceutisch bedrijf. Het bedrijf richt zich op het ontdekken, ontwikkelen, produceren en op de markt brengen van receptgeneesmiddelen, voornamelijk voor de behandeling van ziekten. Het bedrijf richt zich op drie belangrijke therapiegebieden: Oncologie; Cardiovasculair, Renaal & Metabolisme, en Respiratoir & Immunologie. Haar pijplijn vormt een robuuste portefeuille van onderzoekstherapieën in verschillende stadia van klinische ontwikkeling. De onderneming heeft toegang tot technologieën, zowel intern als via haar verschillende samenwerkingsverbanden. Zijn technologieën omvatten akoestische-buistechnologie, geavanceerde moleculaire beeldvorming, cryo-elektronenmicroscopie (cryo-EM), functionele genomica, multi-omica en AstraZeneca iLab. Dankzij zijn akoestische buistechnologie kan het bedrijf miljoenen verbindingen voor biologische screening behandelen en verwerken. Het AstraZeneca iLab is het prototype van een geautomatiseerd laboratorium voor medicinale chemie.
| Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 530.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen